In Experiment 1, although SHR displayed hypertension, urinary protein excretion and plasmin activity were not substantially increased. Accordingly, CM did not prevent hypertension in SHR (SBP (mmHg): SHR 162 vs. SHRþCM 158). In Experiment 2, HS diet induced severe hypertension, marked proteinuria and plasmin activation in urine in SHR/ND mcr-cp. These changes were significantly suppressed by the treatment with CM (SBP (mmHg): HS 230 vs. HSþCM 178; urinary protein (mg/ day): HS 331 vs. HSþCM 86) with the concomitant increase of urinary sodium/potassium ratio, indicating that CM inhibited the ENaC activity. Because CM markedly attenuated proteinuria, we further examined the effect of CM on podocyte injuries. Although CM did not affect body weight, glucose metabolism and adipokine expression in the adipose tissue, it suppressed glomerulosclerosis, the downregulation of nephrin and synaptopodin, and apoptosis of podocytes induced by HS diet. CM also suppressed apoptotic molecules activation by high glucose and aldosterone in cultured murine podocytes. CONCLUSIONS: In conclusion, CM could exert significant antihypertensive and renoprotective effects in a rat model of MetS, suggesting that SP inhibition could be a new therapeutic strategy against salt-sensitive hypertension in MetS.
INTRODUCTION AND AIMS:
The obese Zucker fatty/spontaneously hypertensive heart failure F1 hybrid (ZSF1) rat has been proposed as a viable animal model to study the metabolic cardiorenal syndrome as these rats spontaneously develop diastolic heart failure and chronic kidney disease in the presence of obesity, hyperglycemia and hypertension. Risk factors associated with the metabolic syndrome correlate strongly with salt-sensitivity of blood pressure. In Dahl-salt sensitive rats, a non-obese rat strain commonly used in salt-induced hypertension, males were more susceptible to develop high blood pressures during high salt intake than females. Therefore this study aimed to investigate the effects of obesity and sex on salt-sensitivity in the obese ZSF1 rat model and their lean counterparts. We hypothesized that obesity and male sex would both promote salt-sensitive hypertension. METHODS: Male and female ZSF1 rats, lean as well obese (n¼4-8/subgroup), were either implanted with a deoxycorticosterone acetate (DOCA) pellet and fed a high salt diet (6% NaCl) or with a placebo pellet and fed a normal salt diet from 19 weeks of age. Every two weeks, from 18 (i.e. prior to pellet implantation) to 26 weeks of age, systolic blood pressure (SBP) and 24-hour natriuresis were measured. RESULTS: Obese ZSF1 developed signs of metabolic syndrome, with high cholesterol and triglyceride levels. However, only male obese ZSF1 became hyperglycemic. SBP was higher in both obese compared to lean DOCA þ 6% salt groups (p<0.0001). Natriuresis was higher in male obese vs. lean DOCA þ 6% salt groups (p<0.0001). The SBP response to high salt intake occurred in a stepwise manner in all four DOCA þ 6% salt groups (with constant SBP from 22 to 24 weeks). Comparison of slopes of the natriuresis-pressure relations using 18 and 26 weeks data (figure) showed differences between male obese and lean (p<0.01) and female obese and lean ZSF1 rats (p<0.01), suggesting that obesity promotes salt-sensitivity. Additionally, slopes between obese males and females differed (p<0.01) suggesting that salt-sensitivity was most marked in female obese ZSF1 rats. CONCLUSIONS: Our results in ZSF1 rats indicate i) a phased blood pressure response to high salt intake, ii) an adverse effect of obesity on salt-sensitivity, and iii) a further increased salt-sensitivity in obese females vs. obese males. 
We have shown recently that increasing kidney tissue epoxyeicosatrienoic acids (EETs) by blocking soluble epoxide hydrolase (sEH) and thereby blocking EETs degradation to inactive dihydroxyeicosatrienoic acids (DHETEs) substantially attenuated the progression of chronic kidney disease (CKD) in Ren-2 transgenic hypertensive rats (TGR) subjected to 5/6 renal mass reduction (5/6 NX). In this study we examined if, in this model, addition of sEH inhibition to the complex (dual) renin-angiotensin system (RAS) blockade would bring additional renoprotective effects in already established CKD. METHODS: TGR aged 9 weeks underwent 5/6 NX and then were left untreated for 6 weeks to develop CKD. Then dual RAS blockade: ACE inhibition (trandolapril) þ angiotensin AT1 receptor blockade (losartan) in drinking water was instituted, alone or combined with sEH inhibition (c-AUCB, 3 mg/l in drinking water). During the 60 weeks follow-up period, albuminuria and urinary creatinine excretion was repeatedly determined. The following experimental groups were investigated: 1) sham-operated TGR, 2) untreated 5/6 NX TGR, 3) 5/6 NX TGR þ RAS blockade, 4) 5/6 NX TGR þ RAS þ sEH blockade. Sham-operated transgene-negative normotensive HannoverSprague Dawley (HanSD) rats served as basic controls. In separate groups renal glomerular and tubulointerstitial injury was assessed, and effects of two weeks treatment on systolic blood pressure (SBP, measured by telemetry) and on kidney ANG II, ANG 1-7, EETs and DHETEs levels were determined. RESULTS: All untreated TGR died by week 14 after 5/6 NX. RAS blockade increased the final survival rate to 23%, normalized SBP (116 6 3 vs. 198 6 3 mmHg, p<0.0015), reduced albuminuria (46 6 5 vs. 102 6 12 mg/24 h, p<0.001) and intrarenal ANG II (27 6 8 vs. 189 6 14 fmol/g p<0.0015) and did not alter kidney EETs/DHETEs ratio. After addition of sEH blockade kidney EETs/DHETEs ratio increased to 2.89 6 0.42 (p<0.001 vs. 5/6 NX TGR treated with RAS blockade) and the final survival rate increased to 42%. Albumnuria, glomerular filtration rate, glomerulosclerosis index and index of tubulointersticial injury were also improved comparing with RAS blockade only. CONCLUSIONS: Addition of sEH blockade to the RAS blockade brings about additional renoprotective effects on the CKD progression in 5/6 NX TGR, even when applied in the advanced phase of the disease. 
